Posted in News
Preparations of pirfenidone (Esbriet®) have now been mapped to the dm+d following following confirmation from the Patient Access Scheme Liaison Unit.
The virtual medicinal product (VMP) is included in a number of Tags so the mapping of individual drug lines from Trusts will now be seen. The Tags affected include those for NICE Technology Appraisal TA282 and NICE All Drugs, High Cost Drugs List 2017-19, Patient Access Scheme List, Non-PBr and Passthrough Costs (current).
It is very likely Trusts will see an increase in reported spends.